Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer

Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer

Immune checkpoint inhibitors (ICIs) have made great progress in the field of tumors and have become a promising direction of tumor treatment. With advancements in genomics and bioinformatics technology, it is possible to individually analyze the neoantigens produced by somatic mutations of each pati...

Full description

Bibliographic Details
Main Authors:	Xue-lin Zou, Xiao-bo Li, Hua Ke, Guang-yan Zhang, Qing Tang, Jiao Yuan, Chen-jiao Zhou, Ji-liang Zhang, Rui Zhang, Wei-yong Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Immunology
Subjects:	cancer neoantigen load immune checkpoint inhibitor biomarker prognostic value
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2021.689076/full

Similar Items

Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
by: David Repáraz, et al.
Published: (2022-02-01)

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
by: Luhui Shen, et al.
Published: (2023-05-01)

pTuneos: prioritizing tumor neoantigens from next-generation sequencing data
by: Chi Zhou, et al.
Published: (2019-10-01)

The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma
by: Hirokazu Matsushita, et al.
Published: (2017-08-01)

Progress in Neoantigen Targeted Cancer Immunotherapies
by: Xue-Jiao Han, et al.
Published: (2020-07-01)

The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition
by: Irantzu Anzar, et al.
Published: (2023-09-01)

The Value of Microbes in Cancer Neoantigen Immunotherapy
by: Junrui Tian, et al.
Published: (2023-08-01)

Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy
by: Koji Nagaoka, et al.
Published: (2021-12-01)

Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
by: Juan-Yan Liao, et al.
Published: (2021-05-01)

Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression
by: Kim Bich Nguyen, et al.
Published: (2023-08-01)

Untranslated regions (UTRs) are a potential novel source of neoantigens for personalised immunotherapy
by: Christopher C. T. Sng, et al.
Published: (2024-03-01)

Prognostic role of IL-8 in cancer patients treated with immune checkpoint inhibitors: a system review and meta-analysis
by: Dan Zou, et al.
Published: (2023-08-01)

Cytosolic Delivery of Thiolated Neoantigen Nano‐Vaccine Combined with Immune Checkpoint Blockade to Boost Anti‐Cancer T Cell Immunity
by: Da Zhang, et al.
Published: (2021-03-01)

Analysis of Somatic Mutations in the TCGA-LIHC Whole Exome Sequence to Identify the Neoantigen for Immunotherapy in Hepatocellular Carcinoma
by: Swetha Pulakuntla, et al.
Published: (2023-12-01)

Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
by: Rui Han, et al.
Published: (2023-12-01)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
by: Kunpeng Luo, et al.
Published: (2022-11-01)

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
by: Zhi Pang, et al.
Published: (2023-12-01)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
by: Qiaorui Tan, et al.
Published: (2022-04-01)

Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity
by: Fanqiang Meng, et al.
Published: (2022-12-01)

Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
by: Anders Valind, et al.
Published: (2021-12-01)

Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers
by: Yue Zhu, et al.
Published: (2020-07-01)

Characterization of genomic alterations and neoantigens and analysis of immune infiltration identified therapeutic and prognostic biomarkers in adenocarcinoma at the gastroesophageal junction
by: Yueqiong Lao, et al.
Published: (2022-11-01)

Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
by: Jiawei Shou, et al.
Published: (2022-09-01)

Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
by: John Nemunaitis, et al.
Published: (2023-11-01)

Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
by: Norah A. Alturki
Published: (2023-06-01)

A Novel DNA Repair Gene Signature for Immune Checkpoint Inhibitor-Based Therapy in Gastric Cancer
by: Binbin Yuan, et al.
Published: (2022-05-01)

Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
by: Daniel J. Verdon, et al.
Published: (2021-08-01)

A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer
by: Yongchao Zhang, et al.
Published: (2023-01-01)

Current Trends in Neoantigen-Based Cancer Vaccines
by: Szu-Ying Ho, et al.
Published: (2023-03-01)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021-11-01)

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?
by: Andrea Aran, et al.
Published: (2022-03-01)

Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
by: Di Wu, et al.
Published: (2020-07-01)

Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy
by: Yu Cai, et al.
Published: (2023-01-01)

Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy
by: Masahiro Okada, et al.
Published: (2022-02-01)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
by: Wenxian Wang, et al.
Published: (2020-10-01)

Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1
by: Changbo Sun, et al.
Published: (2021-11-01)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
by: Daniel E. Meyers, et al.
Published: (2019-11-01)

Targeting neoantigens for cancer immunotherapy
by: Xuan Zhao, et al.
Published: (2021-07-01)

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
by: Lucile Pabst, et al.
Published: (2023-04-01)

NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma
by: Xingxing Jian, et al.
Published: (2022-09-01)